Cognition Therapeutics’ dementia drug showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients ...

The trial failed to achieve statistical significance in its goal of improved MCCB neurocognitive composite scores.

Atai Life Sciences’ schizophrenia drug has failed to improve cognition in a phase 2 study, leading the biotech to reaffirm ...

The Alzheimer's Association U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk ( ...

In modern society, sleep is often sacrificed at the altar of productivity. With the demands of work, social obligations, and digital distractions, it ...

After Recognify Life Sciences Inc.’s phase IIb failure in treating the cognitive impairment in those with schizophrenia, the indication is no closer to a U.S. FDA approved therapy. The ...

Two-Phase Study Leads to Monteloeder's Newest Nootropic for Cognitive Performance Provided by PR Newswire Feb 25, 2025 4:00am ...

INmune Bio Reports Phase 2 MINDFuL Trial Results for XPro™ in Early Alzheimer’s Disease, Identifying Subpopulations with Cognitive Benefits June 30, 2025 — 07:42 am EDT ...

“We are excited to advance MT1988 into Phase II trials, where we aim to demonstrate clinical proof of concept in improving cognitive function in patients living with schizophrenia and related ...

The ERUDITE study was the second Phase 2 trial for luvadaxistat. It failed to replicate the cognitive endpoints data seen in the earlier INTERACT™ study, due in part to the large variability ...